Cancer metabolism: Lipid addiction


A recent study utilizing human and mouse breast, colon and lung tumor models has shown that in response to withdrawal of therapy with sunitinib or sorafenib—which are receptor tyrosine kinase inhibitors considered to be antiangiogenic—tumors shift to lipogenesis, rapid regrowth and metastasis. Inhibiting lipogenesis with orlistat could reduce tumor regrowth… (More)
DOI: 10.1038/nm.3659


Cite this paper

@article{Simpson2014CancerML, title={Cancer metabolism: Lipid addiction}, author={Kendra D. Simpson}, journal={Nature Medicine}, year={2014}, volume={20}, pages={813-813} }